PARIS, June 05, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com (http://www.nanobiotix.com/)
+------------+-----------------------+-----------------------------------------+
| | | Total number of voting rights | | | +--------------------+--------------------+ | | Number of Shares |Total voting rights,|Total voting rights,| | Date | Outstanding | theoretical(1) | exercisable(2) | +------------+-----------------------+--------------------+--------------------+
|May 31, 2026| 50,807,903 | 54,304,858 | 54,282,740 | +------------+-----------------------+--------------------+--------------------+
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive,
physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed
on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2)
bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com (http://www.nanobiotix.com) or follow us on LinkedIn (http://www.linkedin.com/company/nanobiotix) and Twitter (http://www.twitter.com/nanobiotix).
_______________________________
(1) The total number of theoretical (or "gross") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of exercisable at a shareholders' meeting (or "net") voting
rights is calculated without taking into account shares for which voting rights
have been suspended as shares held in treasury by the Company. It is released in
order to ensure that the public is properly informed.
Contacts
-------------------------------------------------------------------------------
Nanobiotix
-------------------------------------------------------------------------------

                                             Investor Relations Department
 Communications Department                   Joanne Choi
 Brandon Owens                               VP, Investor Relations (US)
 VP, Communications                          +1 (713) 609-3150

+1 (617) 852-4835

 contact@nanobiotix.com                      Ricky Bhajun
 (mailto:contact@nanobiotix.com)             Director, Investor Relations (EU)
                                             investors@nanobiotix.com
                                             (mailto:investors@nanobiotix.com)

-------------------------------------------------------------------------------
Media Relations
-------------------------------------------------------------------------------

                                             Global - uncapped
 France - HARDY                              Becky Lauer
 Caroline Hardy                              +1 (646) 286-0057
 +33 06 70 33 49 50                          uncappednanobiotix@uncappedcommuni
 carolinehardy@outlook.fr                    cations.com
 (mailto:carolinehardy@outlook.fr)           (mailto:uncappednanobiotix@uncappe
                                             dcommunications.com)

Â